Recent Advances in Primary and Secondary Prevention of Atherosclerotic Stroke

키워드

참고문헌 (214)

1. McGill HC Jr, "Associations of coronary heart disease risk factors with the intermediate lesion of atherosclerosis in youth. The Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group", Arterioscler Thromb Vasc Biol, 20, pp.1998~2004 (2000)[DOI]
2. "Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)", Lancet, 344, pp.1383~1389 (1994)
3. Kim JS, "Risk factors and stroke mechanisms in atherosclerotic stroke: intracranial compared with extracranial and anterior compared with posterior circulation disease", Stroke, 43, pp.3313~3318 (2012)[DOI]
4. O'Donnell MJ, "Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study", Lancet, 388, pp.761~775 (2016)[DOI]
5. Kawachi I, "Smoking cessation and decreased risk of stroke in women", JAMA, 269, pp.232~236 (1993)[DOI]
6. "2008 Physical activity guidelines for Americans"[URL]
7. Strazzullo P, "Excess body weight and incidence of stroke: metaanalysis of prospective studies with 2 million participants", Stroke, 41, pp.e418~e426 (2010)[DOI]
8. Prospective Studies Collaboration, "Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies", Lancet, 373, pp.1083~1096 (2009)[DOI]
9. Eckel RH, "2013 AHA", ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology, Circulation, pp.2014, 129(25 Suppl 2)[DOI]
10. Estruch R, "Primary prevention of cardiovascular disease with a Mediterranean diet", N Engl J Med, 368, pp.1279~1290 (2013)[DOI]
11. Sarkkinen ES, "Feasibility and antihypertensive effect of replacing regular salt with mineral salt-rich in magnesium and potassium-in subjects with mildly elevated blood pressure", Nutr J, 10, pp.88~ (2011)[DOI]
12. Kelli HM, "Association between living in food deserts and cardiovascular risk", Circ Cardiovasc Qual Outcomes, 10, pp.e003532~ (2017)[DOI]
13. Pennlert J, "Socioeconomic status and the risk of stroke recurrence: persisting gaps observed in a nationwide Swedish study 2001 to 2012", Stroke, 48, pp.1518~1523 (2017)[DOI]
14. Baigent C, "Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins", Lancet, 366, pp.1267~1278 (2005)[DOI]
15. Sturgeon JD, "Risk factors for intracerebral hemorrhage in a pooled prospective study", Stroke, 38, pp.2718~2725 (2007)[DOI]
16. Prospective Studies Collaboration, "Blood cholesterol and vascular mortality by age, sex, and blood pressure: a metaanalysis of individual data from 61 prospective studies with 55,000 vascular deaths", Lancet, 370, pp.1829~1839 (2007)[DOI]
17. Iso H, "Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial", N Engl J Med, 320, pp.904~910 (1989)[DOI]
18. Chan DK, "Meta-analysis of the cardiovascular benefits of intensive lipid lowering with statins", Acta Neurol Scand, 124, pp.188~195 (2011)[DOI]
19. Cannon CP, "Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy", J Am Coll Cardiol, 48, pp.438~445 (2006)[DOI]
20. Everett BM, "Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)", Circulation, 121, pp.143~150 (2010)[DOI]
21. Hackam DG, "Statins and intracerebral hemorrhage: collaborative systematic review and meta-analysis", Circulation, 124, pp.2233~2242 (2011)[DOI]
22. D'Agostino RB Sr, "General cardiovascular risk profile for use in primary care: the Framingham Heart Study", Circulation, 117, pp.743~753 (2008)[DOI]
23. Conroy RM, "Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project", Eur Heart J, 24, pp.987~1003 (2003)[DOI]
24. Goff DC Jr, "2013 ACC", AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology, Circulation, pp.2014, 129(25 Suppl 2)[DOI]
25. Lackland DT, "Inclusion of stroke in cardiovascular risk prediction instruments: a statement for healthcare professionals from the American Heart Association", American Stroke Association, 2012, pp.43, 1998~2027
26. Stone NJ, "2013 ACC", AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology, J Am Coll Cardiol, pp.2014, 63(25)[DOI]
27. Cannon CP, "Ezetimibe added to statin therapy after acute coronary syndromes", N Engl J Med, 372, pp.2387~2397 (2015)[DOI]
28. Sabatine MS, "Evolocumab and clinical outcomes in patients with cardiovascular disease", N Engl J Med, 376, pp.1713~1722 (2017)[DOI]
29. Jellinger PS, "American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease", Endocr Pract, 23(Suppl 2), pp.1~87 (2017)
30. Writing Committee, "2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents", J Am Coll Cardiol, 68, pp.92~125 (2016)[DOI]
31. Catapano AL, "2016 ESC", EAS guidelines for the management of dyslipidaemias, 2016, pp.37, 2999~3058
32. "AACE and EAS lipid guidelines" (2017)[URL]
33. Landmesser U, "2017 Update of ESC", EAS Task Force on practical clinical guidance for proprotein convertase subtilisin, Eur Heart J, pp.2018, 39[DOI]
34. Catapano A, "The efficacy and safety of ezetimibe coadministered with statin therapy in various patient groups", Clin Lipidol, 8, pp.13~41 (2013)[DOI]
35. Pagidipati NJ, "Comparison of recommended eligibility for primary prevention statin therapy based on the US Preventive Services Task Force recommendations vs the ACC", AHA guidelines, 2017, pp.317, 1563~1567
36. Kazi DS, "Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease", JAMA, 316, pp.743~753 (2016)[DOI]
37. Amarenco P, "High-dose atorvastatin after stroke or transient ischemic attack", N Engl J Med, 355, pp.549~559 (2006)[DOI]
38. Dhamoon MS, "Risk of myocardial infarction or vascular death after first ischemic stroke: the Northern Manhattan Study", Stroke, 38, pp.1752~1758 (2007)[DOI]
39. Bassand JP, "Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: rationale for comprehensive management of atrial fibrillation", PLoS One, 13, pp.e0191592~ (2018)[DOI]
40. Flint AC, "Inpatient statin use predicts improved ischemic stroke discharge disposition", Neurology, 78, pp.1678~1683 (2012)[DOI]
41. Tsivgoulis G, "Statin pretreatment is associated with better outcomes in large artery atherosclerotic stroke", Neurology, 86, pp.1103~1111 (2016)[DOI]
42. Safouris A, "Statin pretreatment and microembolic signals in large artery atherosclerosis", Arterioscler Thromb Vasc Biol, 37, pp.1415~1422 (2017)[DOI]
43. Tsivgoulis G, "Prevalence of symptomatic intracranial atherosclerosis in Caucasians: a prospective, multicenter, transcranial Doppler study", J Neuroimaging, 24, pp.11~17 (2014)[DOI]
44. Lewington S, "Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies", Lancet, 360, pp.1903~1913 (2002)[DOI]
45. Xie X, "Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and metaanalysis", Lancet, 387, pp.435~443 (2016)[DOI]
46. Katsanos AH, "Blood pressure reduction and secondary stroke prevention: a systematic review and metaregression analysis of randomized clinical trials", Hypertension, 69, pp.171~179 (2017)[DOI]
47. Whelton PK, "2017 ACC", AHA, ABC, pp.ACPM, AGS[DOI]
48. SPS3 Study Group, "Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial", Lancet, 382, pp.507~515 (2013)[DOI]
49. Chaturvedi S, "Risk factor status and vascular events in patients with symptomatic intracranial stenosis", Neurology, 69, pp.2063~2068 (2007)[DOI]
50. Park JH, "Post-stroke diastolic blood pressure and risk of recurrent vascular events", Eur J Neurol, 24, pp.1416~1423 (2017)[DOI]
51. Ovbiagele B, "Level of systolic blood pressure within the normal range and risk of recurrent stroke", JAMA, 306, pp.2137~2144 (2011)
52. Ohira T, "Risk factors for ischemic stroke subtypes: the Atherosclerosis Risk in Communities study", Stroke, 37, pp.2493~2498 (2006)[DOI]
53. Janghorbani M, "Prospective study of type 1 and type 2 diabetes and risk of stroke subtypes: the Nurses' Health Study", Diabetes Care, 30, pp.1730~1735 (2007)[DOI]
54. Woo CH, "Extracellular signal-regulated kinase 5 SUMOylation antagonizes shear stress-induced antiinflammatory response and endothelial nitric oxide synthase expression in endothelial cells", Circ Res, 102, pp.538~545 (2008)[DOI]
55. Banerjee C, "Duration of diabetes and risk of ischemic stroke: the Northern Manhattan Study", Stroke, 43, pp.1212~1217 (2012)[DOI]
56. Garber AJ, "Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm: 2018 executive summary", Endocr Pract, 24, pp.91~120 (2018)[DOI]
57. ACCORD Study Group, "Effects of intensive bloodpressure control in type 2 diabetes mellitus", N Engl J Med, 362, pp.1575~1585 (2010)[DOI]
58. Butalia S, "Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and metaanalysis", Cardiovasc Diabetol, 10, pp.25~ (2011)[DOI]
59. Kobzar G, "Short-term exposure of platelets to glucose impairs inhibition of platelet aggregation by cyclooxygenase inhibitors", Platelets, 22, pp.338~344 (2011)[DOI]
60. American Diabetes Association, "9. Cardiovascular disease and risk management: standards of medical care in diabetes-2018", Diabetes Care, 41(Suppl 1), pp.S86~S104 (2018)[DOI]
61. Zinman B, "Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes", N Engl J Med, 373, pp.2117~2128 (2015)[DOI]
62. Neal B, "Canagliflozin and cardiovascular and renal events in type 2 diabetes", N Engl J Med, 377, pp.644~657 (2017)[DOI]
63. Marso SP, "Liraglutide and cardiovascular outcomes in type 2 diabetes", N Engl J Med, 375, pp.311~322 (2016)[DOI]
64. Dormandy JA, "Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial", Lancet, 366, pp.1279~1289 (2005)[DOI]
65. Mazzone T, "Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial", JAMA, 296, pp.2572~2581 (2006)[DOI]
66. International Stroke Trial Collaborative Group, "The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke", Lancet, 349, pp.1569~1581 (1997)[DOI]
67. ESPRIT Study Group, "Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial", Lancet, 367, pp.1665~1673 (2006)[DOI]
68. Diener HC, "Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study", Lancet Neurol, 7, pp.875~884 (2008)[DOI]
69. CAPRIE Steering Committee, "A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)", Lancet, 348, pp.1329~1339 (1996)[DOI]
70. Ringleb PA, "Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events", Stroke, 35, pp.528~532 (2004)[DOI]
71. Lee M, "Is clopidogrel better than aspirin following breakthrough strokes while on aspirin? A retrospective cohort study", BMJ Open, 4, pp.e006672~ (2014)[DOI]
72. Diener HC, "Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial", Lancet, 364, pp.331~337 (2004)[DOI]
73. Bhatt DL, "Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events", N Engl J Med, 354, pp.1706~1717 (2006)[DOI]
74. Benavente OR, "The secondary prevention of small subcortical strokes (SPS3) study", Int J Stroke, 6, pp.164~175 (2011)[DOI]
75. Wang Y, "Clopidogrel with aspirin in acute minor stroke or transient ischemic attack", N Engl J Med, 369, pp.11~19 (2013)[DOI]
76. Johnston SC, "Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA", N Engl J Med (2018)[DOI]
77. Amarenco P, "Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial", Lancet Neurol, 16, pp.301~310 (2017)[DOI]
78. Kwon SU, "Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis", Stroke, 36, pp.782~786 (2005)[DOI]
79. Kwon SU, "Efficacy and safety of combination antiplatelet therapies in patients with symptomatic intracranial atherosclerotic stenosis", Stroke, 42, pp.2883~2890 (2011)[DOI]
80. Kim DE, "Association between changes in lipid profiles and progression of symptomatic intracranial atherosclerotic stenosis: a prospective multicenter study", Stroke, 43, pp.1824~1830 (2012)[DOI]
81. Kim BJ, "Prevention of cardiovascular events in Asian patients with ischaemic stroke at high risk of cerebral haemorrhage (PICASSO): a multicentre, randomised controlled trial", Lancet Neurol, 17, pp.509~518 (2018)[DOI]
82. Eikelboom JW, "Rivaroxaban with or without aspirin in stable cardiovascular disease", N Engl J Med, 377, pp.1319~1330 (2017)[DOI]
83. Mega JL, "Rivaroxaban in patients with a recent acute coronary syndrome", N Engl J Med, 366, pp.9~19 (2012)[DOI]
84. Katsanos AH, "Novel oral anticoagulants for the secondary prevention of cerebral ischemia: a network metaanalysis", Ther Adv Neurol Disord, 9, pp.359~368 (2016)[DOI]
85. Anand SS, "Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial", Lancet (2017)[DOI]
86. Marnane M, "Carotid plaque inflammation on 18F-fluorodeoxyglucose positron emission tomography predicts early stroke recurrence", Ann Neurol, 71, pp.709~718 (2012)[DOI]
87. Ridker PM, "Antiinflammatory therapy with canakinumab for atherosclerotic disease", N Engl J Med, 377, pp.1119~1131 (2017)[DOI]
88. "Canakinumab (Ilaris): Common Drug Review" (2016)[URL]
89. Nidorf SM, "Lowdose colchicine for secondary prevention of cardiovascular disease", J Am Coll Cardiol, 61, pp.404~410 (2013)[DOI]
90. Tsivgoulis G, "The role of colchicine in the prevention of cerebrovascular ischemia", Curr Pharm Des, 24, pp.668~674 (2018)[DOI]
91. "Colchicine for prevention of vascular inflammation in non-cardioembolic stroke (CONVINCE)" (2017)[URL]
92. Rothwell PM, "Analysis of pooled data from the randomised controlled trials of endarterectomy for symptomatic carotid stenosis", Lancet, 361, pp.107~116 (2003)[DOI]
93. Howard VJ, "Influence of sex on outcomes of stenting versus endarterectomy: a subgroup analysis of the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST)", Lancet Neurol, 10, pp.530~537 (2011)[DOI]
94. Rantner B, "Early endarterectomy carries a lower procedural risk than early stenting in patients with symptomatic stenosis of the internal carotid artery: results from 4 randomized controlled trials", Stroke, 48, pp.1580~1587 (2017)[DOI]
95. Stromberg S, "Very urgent carotid endarterectomy confers increased procedural risk", Stroke, 43, pp.1331~1335 (2012)[DOI]
96. Tsivgoulis G, "Clopidogrel load for emboli reduction in patients with symptomatic carotid stenosis undergoing urgent carotid endarterectomy", Stroke, 43, pp.1957~1960 (2012)[DOI]
97. Jones DW, "Dual antiplatelet therapy reduces stroke but increases bleeding at the time of carotid endarterectomy", J Vasc Surg, 63, pp.1262~1270 (2016)[DOI]
98. Rothwell PM, "Sex difference in the effect of time from symptoms to surgery on benefit from carotid endarterectomy for transient ischemic attack and nondisabling stroke", Stroke, 35, pp.2855~2861 (2004)[DOI]
99. Calvet D, "Carotid stenting: is there an operator effect? A pooled analysis from the carotid stenting trialists' collaboration", Stroke, 45, pp.527~532 (2014)[DOI]
100. Kernan WN, "Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association", American Stroke Association, 2014, pp.45, 2160~2236
101. Hugl B, "Effect of age and gender on restenosis after carotid endarterectomy", Ann Vasc Surg, 20, pp.602~608 (2006)[DOI]
102. De Rango P, "Management of carotid stenosis in women: consensus document", Neurology, 80, pp.2258~2268 (2013)[DOI]
103. Molina CA, "Carotid wars episode VI: return of the standard", Stroke, 44, pp.2959~2960 (2013)[DOI]
104. Barnett HJ, "Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators", N Engl J Med, 339, pp.1415~1425 (1998)[DOI]
105. Rerkasem K, "Systematic review of randomized controlled trials of patch angioplasty versus primary closure during carotid endarterectomy", Stroke, 41, pp.e55~e56 (2010)[DOI]
106. Brott TG, "Stenting versus endarterectomy for treatment of carotid-artery stenosis", N Engl J Med, 363, pp.11~23 (2010)[DOI]
107. Sharma VK, "Abstract 147: plaque inflammation is associated with early cerebral ischemic events in symptomatic carotid stenosis", Stroke, 49, pp.A147~ (2018)[DOI]
108. Kim DE, "Protease imaging of human atheromata captures molecular information of atherosclerosis, complementing anatomic imaging", Arterioscler Thromb Vasc Biol, 30, pp.449~456 (2010)[DOI]
109. Economopoulos KP, "Carotid artery stenting versus carotid endarterectomy: a comprehensive meta-analysis of short-term and long-term outcomes", Stroke, 42, pp.687~692 (2011)[DOI]
110. Fine-Edelstein JS, "Precursors of extracranial carotid atherosclerosis in the Framingham Study", Neurology, 44, pp.1046~1050 (1994)[DOI]
111. Meschia JF, "Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association", American Stroke Association, 2014, pp.45, 3754~3832
112. Abbott AL, "Medical (nonsurgical) intervention alone is now best for prevention of stroke associated with asymptomatic severe carotid stenosis: results of a systematic review and analysis", Stroke, 40, pp.e573~e583 (2009)[DOI]
113. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study, "Endarterectomy for asymptomatic carotid artery stenosis", JAMA, 273, pp.1421~1428 (1995)[DOI]
114. Halliday A, "Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial", Lancet, 363, pp.1491~1502 (2004)[DOI]
115. Halliday A, "10-Year stroke prevention after successful carotid endarterectomy for asymptomatic stenosis (ACST-1): a multicentre randomised trial", Lancet, 376, pp.1074~1084 (2010)[DOI]
116. Baker WH, "Effect of contralateral occlusion on long-term efficacy of endarterectomy in the asymptomatic carotid atherosclerosis study (ACAS). ACAS Investigators", Stroke, 31, pp.2330~2334 (2000)[DOI]
117. Nicolaides AN, "Severity of asymptomatic carotid stenosis and risk of ipsilateral hemispheric ischaemic events: results from the ACSRS study", Eur J Vasc Endovasc Surg, 30, pp.275~284 (2005)[DOI]
118. Al-Lamee R, "Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial", Lancet, 391, pp.31~40 (2018)[DOI]
119. Stergiopoulos K, "Initial coronary stent implantation with medical therapy vs medical therapy alone for stable coronary artery disease: meta-analysis of randomized controlled trials", Arch Intern Med, 172, pp.312~319 (2012)[DOI]
120. Brown DL, "Last nail in the coffin for PCI in stable angina?", Lancet, 391, pp.3~4 (2018)[DOI]
121. McPhee JT, "Carotid artery stenting has increased rates of postprocedure stroke, death, and resource utilization than does carotid endarterectomy in the United States, 2005", J Vasc Surg, 48, pp.1442~1450 (2008)[DOI]
122. Naylor AR, "Time to rethink management strategies in asymptomatic carotid artery disease", Nat Rev Cardiol, 9, pp.116~124 (2011)
123. Naylor AR, "Why is the management of asymptomatic carotid disease so controversial?", Surgeon, 13, pp.34~43 (2015)[DOI]
124. Rothwell PM, "Low risk of ischemic stroke in patients with reduced internal carotid artery lumen diameter distal to severe symptomatic carotid stenosis: cerebral protection due to low poststenotic flow? On behalf of the European Carotid Surgery Trialists' Collaborative Group", Stroke, 31, pp.622~630 (2000)[DOI]
125. Kargiotis O, "The role of neurosonology in the diagnosis and management of patients with carotid artery disease: a review", J Neuroimaging, 28, pp.239~251 (2018)[DOI]
126. Geroulakos G, "Ultrasonographic carotid plaque morphology in predicting stroke risk", Br J Surg, 83, pp.582~587 (1996)[DOI]
127. Brinjikji W, "Ultrasound characteristics of symptomatic carotid plaques: a systematic review and metaanalysis", Cerebrovasc Dis, 40, pp.165~174 (2015)[DOI]
128. Griffin M, "Normalisation of ultrasonic images of atherosclerotic plaques and reproducibility of grey scale median using dedicated software", Int Angiol, 26, pp.372~377 (2007)
129. Biasi GM, "Carotid plaque echolucency increases the risk of stroke in carotid stenting: the Imaging in Carotid Angioplasty and Risk of Stroke (ICAROS) study", Circulation, 110, pp.756~762 (2004)[DOI]
130. Markus HS, "Asymptomatic embolisation for prediction of stroke in the Asymptomatic Carotid Emboli Study (ACES): a prospective observational study", Lancet Neurol, 9, pp.663~671 (2010)[DOI]
131. Saba L, "CT and ultrasound in the study of ulcerated carotid plaque compared with surgical results: potentialities and advantages of multidetector row CT angiography", AJNR Am J Neuroradiol, 28, pp.1061~1066 (2007)[DOI]
132. Schroeder S, "Noninvasive detection and evaluation of atherosclerotic coronary plaques with multislice computed tomography", J Am Coll Cardiol, 37, pp.1430~1435 (2001)[DOI]
133. Singh N, "Moderate carotid artery stenosis: MR imagingdepicted intraplaque hemorrhage predicts risk of cerebrovascular ischemic events in asymptomatic men", Radiology, 252, pp.502~508 (2009)[DOI]
134. Meschia JF, "Evaluation and management of atherosclerotic carotid stenosis", Mayo Clin Proc, 92, pp.1144~1157 (2017)[DOI]
135. Mott M, "CREST-2: identifying the best method of stroke prevention for carotid artery stenosis: national institute of neurological disorders and stroke organizational update", Stroke, 48, pp.e130~e131 (2017)[DOI]
136. "Carotid endarterectomy versus carotid artery stenting in asymptomatic patients (ACST-2)" (2017)[URL]
137. "ECST-2. Protocol summary: version 3.10" (2015)[URL]
138. Adams HP Jr, "Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment", Stroke, 24, pp.35~41 (1993)[DOI]
139. Naghavi M, "From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I", Circulation, 108, pp.1664~1672 (2003)[DOI]
140. Falk E, "Angina pectoris and disease progression", Circulation, 92, pp.2033~2035 (1995)[DOI]
141. Stary HC, "Natural history and histological classification of atherosclerotic lesions: an update", Arterioscler Thromb Vasc Biol, 20, pp.1177~1178 (2000)[DOI]
142. Saam T, "Comparison of symptomatic and asymptomatic atherosclerotic carotid plaque features with in vivo MR imaging", Radiology, 240, pp.464~472 (2006)[DOI]
143. Freilinger TM, "Prevalence of nonstenosing, complicated atherosclerotic plaques in cryptogenic stroke", JACC Cardiovasc Imaging, 5, pp.397~405 (2012)[DOI]
144. Coutinho JM, "Nonstenotic carotid plaque on CT angiography in patients with cryptogenic stroke", Neurology, 87, pp.665~672 (2016)[DOI]
145. Zhao X, "Chinese Atherosclerosis Risk Evaluation (CARE II) study: a novel cross-sectional, multicentre study of the prevalence of high-risk atherosclerotic carotid plaque in Chinese patients with ischaemic cerebrovascular events-design and rationale", Stroke Vasc Neurol, 2, pp.15~20 (2017)[DOI]
146. Selwaness M, "Determinants of carotid atherosclerotic plaque burden in a stroke-free population", Atherosclerosis, 255, pp.186~192 (2016)[DOI]
147. Palm F, "Etiology, risk factors and sex differences in ischemic stroke in the Ludwigshafen Stroke Study, a populationbased stroke registry", Cerebrovasc Dis, 33, pp.69~75 (2012)[DOI]
148. Bogiatzi C, "SPARKLE (Subtypes of Ischaemic Stroke Classification System), incorporating measurement of carotid plaque burden: a new validated tool for the classification of ischemic stroke subtypes", Neuroepidemiology, 42, pp.243~251 (2014)[DOI]
149. Spence JD, "Carotid plaque area: a tool for targeting and evaluating vascular preventive therapy", Stroke, 33, pp.2916~2922 (2002)[DOI]
150. Iemolo F, "Sex differences in carotid plaque and stenosis", Stroke, 35, pp.477~481 (2004)[DOI]
151. Hyafil F, "High-risk plaque features can be detected in non-stenotic carotid plaques of patients with ischaemic stroke classified as cryptogenic using combined (18)F-FDG PET", MR imaging, 2016, pp.43, 270~279
152. Marquardt L, "Incidence and prognosis of > or = 50% symptomatic vertebral or basilar artery stenosis: prospective population-based study", Brain, 132, pp.982~988 (2009)
153. Al-Ali F, "Vertebral artery ostium atherosclerotic plaque as a potential source of posterior circulation ischemic stroke: result from borgess medical center vertebral artery ostium stenting registry", Stroke, 42, pp.2544~2549 (2011)[DOI]
154. Rozeman AD, "Duplex ultrasonography for the detection of vertebral artery stenosis: a comparison with CT angiography", Brain Behav, 7, pp.e00750~ (2017)[DOI]
155. Khan S, "Imaging of vertebral artery stenosis: a systematic review", J Neurol Neurosurg Psychiatry, 78, pp.1218~1225 (2007)[DOI]
156. Coward LJ, "Long-term outcome after angioplasty and stenting for symptomatic vertebral artery stenosis compared with medical treatment in the Carotid And Vertebral Artery Transluminal Angioplasty Study (CAVATAS): a randomized trial", Stroke, 38, pp.1526~1530 (2007)[DOI]
157. Compter A, "Stenting versus medical treatment in patients with symptomatic vertebral artery stenosis: a randomised open-label phase 2 trial", Lancet Neurol, 14, pp.606~614 (2015)[DOI]
158. Markus HS, "Stenting for symptomatic vertebral artery stenosis: The Vertebral Artery Ischaemia Stenting Trial", Neurology, 89, pp.1229~1236 (2017)[DOI]
159. Amin-Hanjani S, "Hemodynamic features of symptomatic vertebrobasilar disease", Stroke, 46, pp.1850~1856 (2015)[DOI]
160. Amin-Hanjani S, "Effect of hemodynamics on stroke risk in symptomatic atherosclerotic vertebrobasilar occlusive disease", JAMA Neurol, 73, pp.178~185 (2016)[DOI]
161. Amin-Hanjani S, "Higher stroke risk with lower blood pressure in hemodynamic vertebrobasilar disease: analysis from the VERiTAS Study", J Stroke Cerebrovasc Dis, 26, pp.403~410 (2017)[DOI]
162. Turan TN, "Relationship between blood pressure and stroke recurrence in patients with intracranial arterial stenosis", Circulation, 115, pp.2969~2975 (2007)[DOI]
163. Cohen A, "Aortic plaque morphology and vascular events: a follow-up study in patients with ischemic stroke. FAPS Investigators. French Study of Aortic Plaques in Stroke", Circulation, 96, pp.3838~3841 (1997)[DOI]
164. Amarenco P, "The prevalence of ulcerated plaques in the aortic arch in patients with stroke", N Engl J Med, 326, pp.221~225 (1992)[DOI]
165. Amarenco P, "Atherosclerotic disease of the aortic arch and the risk of ischemic stroke", N Engl J Med, 331, pp.1474~1479 (1994)[DOI]
166. Mitusch R, "Vascular events during follow-up in patients with aortic arch atherosclerosis", Stroke, 28, pp.36~39 (1997)[DOI]
167. Rundek T, "Association between large aortic arch atheromas and high-intensity transient signals in elderly stroke patients", Stroke, 30, pp.2683~2686 (1999)[DOI]
168. Petty GW, "Population-based study of the relationship between atherosclerotic aortic debris and cerebrovascular ischemic events", Mayo Clin Proc, 81, pp.609~614 (2006)[DOI]
169. Meissner I, "Atherosclerosis of the aorta: risk factor, risk marker, or innocent bystander? A prospective population-based transesophageal echocardiography study", J Am Coll Cardiol, 44, pp.1018~1024 (2004)[DOI]
170. Harloff A, "Retrograde embolism from the descending aorta: visualization by multidirectional 3D velocity mapping in cryptogenic stroke", Stroke, 40, pp.1505~1508 (2009)[DOI]
171. Harloff A, "Complex plaques in the proximal descending aorta: an underestimated embolic source of stroke", Stroke, 41, pp.1145~1150 (2010)[DOI]
172. Katsanos AH, "Complex atheromatous plaques in the descending aorta and the risk of stroke: a systematic review and meta-analysis", Stroke, 45, pp.1764~1770 (2014)[DOI]
173. Chatzikonstantinou A, "CT angiography of the aorta is superior to transesophageal echocardiography for determining stroke subtypes in patients with cryptogenic ischemic stroke", Cerebrovasc Dis, 33, pp.322~328 (2012)[DOI]
174. Harloff A, "3D MRI provides improved visualization and detection of aortic arch plaques compared to transesophageal echocardiography", J Magn Reson Imaging, 36, pp.604~611 (2012)[DOI]
175. Wehrum T, "Prevalence of potential retrograde embolization pathways in the proximal descending aorta in stroke patients and controls", Cerebrovasc Dis, 38, pp.410~417 (2014)[DOI]
176. Lima JA, "Statin-induced cholesterol lowering and plaque regression after 6 months of magnetic resonance imaging-monitored therapy", Circulation, 110, pp.2336~2341 (2004)[DOI]
177. Tahara N, "Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography", J Am Coll Cardiol, 48, pp.1825~1831 (2006)[DOI]
178. Mak W, "A possible explanation for the racial difference in distribution of largearterial cerebrovascular disease: ancestral European settlers evolved genetic resistance to atherosclerosis, but confined to the intracranial arteries", Med Hypotheses, 65, pp.637~648 (2005)[DOI]
179. Jung KH, "Secular trends in ischemic stroke characteristics in a rapidly developed country: results from the Korean Stroke Registry Study (secular trends in Korean stroke)", Circ Cardiovasc Qual Outcomes, 5, pp.327~334 (2012)[DOI]
180. 방오영, "Intracranial Atherosclerosis: Current Understanding and Perspectives", 대한뇌졸중영문학회지, 16(1), pp.27~35 (2014), 대한뇌졸중학회[DOI]
181. Gao S, "Microembolic signal predicts recurrent cerebral ischemic events in acute stroke patients with middle cerebral artery stenosis", Stroke, 35, pp.2832~2836 (2004)[DOI]
182. Wu X, "Microembolic signals detected with transcranial Doppler sonography differ between symptomatic and asymptomatic middle cerebral artery stenoses in Northeast China", PLoS One, 9, pp.e88986~ (2014)[DOI]
183. Chimowitz MI, "Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis", N Engl J Med, 352, pp.1305~1316 (2005)[DOI]
184. Wang Y, "Prevalence and outcomes of symptomatic intracranial large artery stenoses and occlusions in China: the Chinese Intracranial Atherosclerosis (CICAS) Study", Stroke, 45, pp.663~669 (2014)[DOI]
185. Louis R Caplan, "Lacunar Infarction and Small Vessel Disease: Pathology and Pathophysiology", 대한뇌졸중영문학회지, 17(1), pp.2~6 (2015), 대한뇌졸중학회
186. Wen-jie Yang, "Intracranial Atherosclerosis: From Microscopy to High-Resolution Magnetic Resonance Imaging", 대한뇌졸중영문학회지, 19(3), pp.249~260 (2017), 대한뇌졸중학회
187. Yamamoto Y, "Characteristics of intracranial branch atheromatous disease and its association with progressive motor deficits", J Neurol Sci, 304, pp.78~82 (2011)[DOI]
188. Harteveld AA, "High-resolution intracranial vessel wall MRI in an elderly asymptomatic population: comparison of 3T and 7T", Eur Radiol, 27, pp.1585~1595 (2017)[DOI]
189. Harteveld AA, "Quantitative intracranial atherosclerotic plaque characterization at 7T MRI: an ex vivo study with histologic validation", AJNR Am J Neuroradiol, 37, pp.802~810 (2016)[DOI]
190. Chen XY, "Middle cerebral artery atherosclerosis: histological comparison between plaques associated with and not associated with infarct in a postmortem study", Cerebrovasc Dis, 25, pp.74~80 (2008)[DOI]
191. Xu WH, "Middle cerebral artery intraplaque hemorrhage: prevalence and clinical relevance", Ann Neurol, 71, pp.195~198 (2012)[DOI]
192. Chimowitz MI, "Stenting versus aggressive medical therapy for intracranial arterial stenosis", N Engl J Med, 365, pp.993~1003 (2011)[DOI]
193. Kern R, "Stroke recurrences in patients with symptomatic vs asymptomatic middle cerebral artery disease", Neurology, 65, pp.859~864 (2005)[DOI]
194. Matsui R, "A prospective study of asymptomatic intracranial atherosclerotic stenosis in neurologically normal volunteers in a Japanese cohort", Front Neurol, 7, pp.39~ (2016)
195. Roth W, "Histopathological differences between the anterior and posterior brain arteries as a function of aging", Stroke, 48, pp.638~644 (2017)[DOI]
196. Qureshi AI, "Stroke-free survival and its determinants in patients with symptomatic vertebrobasilar stenosis: a multicenter study", Neurosurgery, 52, pp.1033~1039 (2003)
197. Kasner SE, "Predictors of ischemic stroke in the territory of a symptomatic intracranial arterial stenosis", Circulation, 113, pp.555~563 (2006)[DOI]
198. Waddy SP, "Racial differences in vascular risk factors and outcomes of patients with intracranial atherosclerotic arterial stenosis", Stroke, 40, pp.719~725 (2009)[DOI]
199. Wong KS, "Intracranial stenosis in Chinese patients with acute stroke", Neurology, 50, pp.812~813 (1998)[DOI]
200. Arenillas JF, "Progression and clinical recurrence of symptomatic middle cerebral artery stenosis: a long-term follow-up transcranial Doppler ultrasound study", Stroke, 32, pp.2898~2904 (2001)[DOI]
201. Leng X, "Computational fluid dynamics modeling of symptomatic intracranial atherosclerosis may predict risk of stroke recurrence", PLoS One, 9, pp.e97531~ (2014)[DOI]
202. Hoshino T, "Prevalence of systemic atherosclerosis burdens and overlapping stroke etiologies and their associations with long-term vascular prognosis in stroke with intracranial atherosclerotic disease", JAMA Neurol, 75, pp.203~211 (2018)[DOI]
203. Liebeskind DS, "Collaterals dramatically alter stroke risk in intracranial atherosclerosis", Ann Neurol, 69, pp.963~974 (2011)[DOI]
204. Lau AY, "Significance of good collateral compensation in symptomatic intracranial atherosclerosis", Cerebrovasc Dis, 33, pp.517~524 (2012)[DOI]
205. Waters MF, "Factors associated with recurrent ischemic stroke in the medical group of the SAMMPRIS trial", JAMA Neurol, 73, pp.308~315 (2016)[DOI]
206. Kim BS, "Burden of intracranial atherosclerosis is associated with long-term vascular outcome in patients with ischemic stroke", Stroke, 48, pp.2819~2826 (2017)[DOI]
207. Jung JM, "Predictors of recurrent stroke in patients with symptomatic intracranial arterial stenosis", Stroke, 43, pp.2785~2787 (2012)[DOI]
208. Ovbiagele B, "Impact of metabolic syndrome on prognosis of symptomatic intracranial atherostenosis", Neurology, 66, pp.1344~1349 (2006)[DOI]
209. Wang X, "The effectiveness of dual antiplatelet treatment in acute ischemic stroke patients with intracranial arterial stenosis: a subgroup analysis of CLAIR study", Int J Stroke, 8, pp.663~668 (2013)[DOI]
210. Sangha RS, "Challenges in the medical management of symptomatic intracranial stenosis in an urban setting", Stroke, 48, pp.2158~2163 (2017)[DOI]
211. Liu L, "Dual antiplatelet therapy in stroke and ICAS: subgroup analysis of CHANCE", Neurology, 85, pp.1154~1162 (2015)[DOI]
212. Tsivgoulis G, "Percutaneous transluminal angioplasty and stenting for symptomatic intracranial arterial stenosis: a systematic review and meta-analysis", Ther Adv Neurol Disord, 9, pp.351~358 (2016)[DOI]
213. Fiorella D, "Detailed analysis of periprocedural strokes in patients undergoing intracranial stenting in Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS)", Stroke, 43, pp.2682~2688 (2012)[DOI]
214. Gao P, "China Angioplasty and Stenting for Symptomatic Intracranial Severe Stenosis (CASSISS): a new, prospective, multicenter, randomized controlled trial in China", Interv Neuroradiol, 21, pp.196~204 (2015)[DOI]

관련 논문AI추천